×

Ackman: VRX undervalued, phone ringing for potential asset buyers

12:11 PM ET Mon, 2 May 2016

Bill Ackman, Pershing Square Capital CEO and portfolio manager, weighs in on when to invest in Valeant Pharmaceuticals.